A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared
A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE: NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or ALL. The recommendation clears the way for a formal FDA green light, and it begins a new era in the fight against cancer.
Chimeric antigen receptor T-cell therapy, or CAR-T, is a new approach involving the re-engineering of a patient's T-cells so that they can better find and destroy cancer cells. T-cells are collected from a patient, sent off to a facility where they are altered, and then they're infused back into the patient.
Image source: Getty Images.
Source: Fool.com
Amgen Inc. Aktie
Uneingeschränkte Unterstützung für Amgen Inc., ausschließlich Buy-Einschätzungen.
Ein Kursziel von 304 € für Amgen Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 289.1 €.